Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;12(2):333-342.
doi: 10.1007/s40121-022-00746-1. Epub 2022 Dec 30.

New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease

Camille Nelson Kotton  1   2 , Nassim Kamar  3   4   5
Affiliations
Review

New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease

Camille Nelson Kotton et al. Infect Dis Ther. 2023 Feb.

Abstract

Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ transplantation, with a significant impact on transplant outcomes. Prevention strategies decrease the risk of CMV disease, although CMV still occurs in up to 50% of high-risk patients. Ganciclovir (GCV) and valganciclovir (VGCV) are the main drugs currently used for preventing and treating CMV. Emerging data suggest that letermovir is as effective as VGCV with fewer hematological side effects. Refractory and resistant CMV also still occur in solid-organ-transplant patients. Maribavir has been shown to be effective and have less toxicity in the treatment of refractory and resistant CMV. In this review paper, we discuss prevention strategies, refractory and resistant CMV, and drug-related side effects and their impact, as well as optimal use of novel anti-CMV therapies.

Keywords: Letermovir; Maribavir; Organ transplantation; Prevention; Refractory CMV; Resistant CMV.

PubMed Disclaimer

References

    1. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13(3):24–40. doi: 10.1111/ajt.12006. - DOI - PubMed
    1. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989;261(24):3607–3609. doi: 10.1001/jama.1989.03420240121038. - DOI - PubMed
    1. Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, et al. Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(4):617–631. doi: 10.1093/cid/cix793. - DOI - PubMed
    1. Limaye AP, Babu TM, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 2020;34:1. doi: 10.1128/CMR.00043-19. - DOI - PMC - PubMed
    1. Tang Y, Guo J, Li J, Zhou J, Mao X, Qiu T. Risk factors for cytomegalovirus infection and disease after kidney transplantation: a meta-analysis. Transpl Immunol. 2022;74:101677. doi: 10.1016/j.trim.2022.101677. - DOI - PubMed

LinkOut - more resources